Eikon Therapeutics

Eikon is a pioneering drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells. We are engineering a battery of innovative tools and technologies for biological exploration in drug discovery and beyond.

Eikon thrives on the energy and creativity of interdisciplinary teams. We are physicists and chemists, biologists and engineers. We spend our days context-switching between multiple scientific languages. We work with lasers, super-resolution microscopes, and robot arms. We leverage machine learning, cell line engineering, and the collective intelligence of world-class scientists and technologists to observe therapeutically relevant biology in a way no one has before.

We’re endlessly curious, intellectually honest and we love what we do. We’re driven to learn the true mechanisms of biology and pharmacology at the molecular level, to make the biggest difference in as many lives as possible.

  • NextGen Class of 2022
  • 2024 Best Places to Work
3929 Point Eden Way
Hayward, CA 94545
  • Featured Employer
Roger Perlmutter’s company announced the addition Thursday of myriad early- to mid-stage assets in the cancer and neurodegenerative disease spaces.
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they’ve done to earn their place on the list - and what’s on the horizon.
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that the company will provide an overview of clinical and preclinical progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th at 9:00 AM Pacific Time.
Eikon Therapeutics, Inc. today announced that CEO and Board Chair, Roger M. Perlmutter, M.D., Ph.D., will provide a business update highlighting pipeline and clinical development progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 AM Pacific Standard Time.
Eikon Therapeutics, Inc. announced today the appointment of Robert (“Robbie”) L. Huffines as an independent director effective December 1, 2023.
Eikon Therapeutics, Inc. announced today that it has completed the previously announced integration of TLR 7 and 8 co-agonists into its clinical development program, and that it expects to discuss the further development of these molecules with the U.S. Food and Drug Administration (FDA) in the fourth quarter.
Cleave Therapeutics, Inc. today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.
IMPACT Therapeutics and Eikon Therapeutics today announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023.
Eikon Therapeutics, Inc. today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review.
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline.
Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a lease with Alexandria Real Estate Equities, Inc.